SAN DIEGO--(BUSINESS WIRE)--
Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage,
Chief Executive Officer of Retrophin, will be presenting at the 2015
Leerink Global Healthcare Conference in New York City on Wednesday,
February 11 at 2:40 p.m. ET.
A live webcast will be available at www.retrophin.com
in the Events & Presentations section. A replay of the webcast will be
archived on the Retrophin website and accessible for 90 days.
About Retrophin
Retrophin is a pharmaceutical company focused on the development,
acquisition and commercialization of drugs for the treatment of serious,
catastrophic or rare diseases for which there are currently no viable
options for patients. The Company's approved products include Chenodal®,
Thiola® and Vecamyl®, and its pipeline includes compounds for several
catastrophic diseases, including focal segmental glomerulosclerosis
(FSGS), pantothenate kinase-associated neurodegeneration (PKAN),
schizophrenia, infantile spasms, nephrotic syndrome and others. For
additional information, please visit www.retrophin.com.
Retrophin, Inc.
Chris Cline, CFA
646-564-3680
Manager,
Investor Relations
IR@retrophin.com
Source: Retrophin, Inc.
News Provided by Acquire Media